SCHEMBL8306576

SCHEMBL8306576

Cc1ccc(N2CCCOC2=O)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.38
P2RX7 Q99572 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
DGAT1 O75907 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ATR Q13535 1/20 0.35
ATRIP Q8WXE1 1/20 0.35
CMA1 P23946 1/20 0.35
BCHE P06276 1/20 0.34
F10 P00742 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8306548 0.85 ALDH1A1 (0.43) L3MBTL1P2RX7MEN1KMT2AMAPT
SCHEMBL4515367 0.84 MAPT (0.54) L3MBTL1P2RX7MEN1KMT2ASMN1; SMN2
SCHEMBL8306977 0.82 LMNA (0.39) P2RX7SMN1; SMN2HSD17B10ALDH1A1SRD5A1
SCHEMBL14547591 0.79 ALDH1A1 (0.36) P2RX7KMT2AHSD17B10ATRATRIP
SCHEMBL4508548 0.78 MAPT (0.48) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL8305501 0.77 HSD17B10 (0.50) METAP2L3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL8305486 0.76 HSD17B10 (0.45) METAP2MEN1KMT2AGAAHSD17B10
SCHEMBL29182832 0.76 MAPT (0.39) P2RX7SMN1; SMN2GAAMAPTCMA1
SCHEMBL8306647 0.75 SMN1; SMN2 (0.47) METAP2MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL76885 0.75 ALDH1A1 (0.51) L3MBTL1MEN1KMT2ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS F12, F2, PEPD METAP2 128/4885L3MBTL1 2178/4885P2RX7 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.